Business Wire
11 Nov 2026, 02:31 UTC · 14h ago
Impact · against what's priced in
ImmunityBio's participation in major London conferences is a routine investor relations activity, though it provides a platform to discuss bladder cancer study progress. While generally positive, the news lacks the material catalyst required to move the stock independently.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
ImmunityBio senior leadership will participate in the Jefferies Global Healthcare Conference and UBS Global Biopharma Conference from November 15-20, 2026.
Newannounced today (Nov 11)
So whatInvestor conferences often precede material updates or partnership leaks within the following 2-week window.
More positive than 42% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The company's presence at Jefferies and UBS conferences, combined with mention of the QUILT-2.005 bladder cancer study, signals active engagement with the investment community and progress in its clinical pipeline.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of ticker scores this week
The company is presenting at major healthcare conferences and reports positive progress in its bladder cancer study.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
16h ago
−1.5%
Price is moving against the score
$6.65 vs $6.75 close before publication (Nov 10) · not market-adjusted
IBRX chart →
